announcement, page-85

Nuts,

I have always valued your opinion, why , because you consider and post on both the positives and negatives. Dendreon at one stage had a $5B+ market, why, because similar expectations/forward looking valuations were built into the stock price.We all know the outcome there to date. Your valuation of Prima's stock price is based on forward looking valuations and therefore highlights were the stock may trade at some point,if positive developments for Cvac continue.So therefore are we overvalued based on forward looking valuations, no, are we overvalued based on market cap comparison with our US peers at a similar stage of development, yes, hence why no appreciation in share price.I haven't got a problem with your post commercialization valuations and that is the reason why this stock has the interest from retail investors/traders because it has an easy story for them to follow, has hugh potential if Cvac shows potential, but it is the IF's that keep knocking it back. And two of those big IF's are, will Cvac improve PFS and OS in ovarian cancer,an outcome that will not be available on a meaningful statistical basis for many years to come, and two, the success of other immunotherapy stocks in the immunotherapy sector itself as we move forward during that period. As for point one, no results in 4 years hence why the share price appreciation has stalled (first traded at 20 cents over 2 years ago)as the market awaits Phase 2b interim results for some indication of the possibility of continued success from this point on,and point 2 is something we all need to keep an eye on. Cheers